New treatment target found for CDKL5 deficiency disorder
Scientists at the Francis Crick Institute have found a new treatment target for CDKL5 deficiency disorder (CDD), one of the most common types of genetic epilepsy.
Stay updated with breaking news from Brain Development Laboratory. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Scientists at the Francis Crick Institute have found a new treatment target for CDKL5 deficiency disorder (CDD), one of the most common types of genetic epilepsy.
Developmental and epileptic encephalopathies are rare forms of epilepsy that can begin in childhood. The patients are treated with generic antiepileptic drugs. | Health
Researchers at the Francis Crick Institute, UCL and MSD have identified a potential treatment target for a genetic type of epilepsy.
<p>Researchers at the Francis Crick Institute, <a href="https://www.ucl.ac.uk/">UCL</a> and <a href="https://www.msd.com/">MSD</a> have identified a potential treatment target for a genetic type of epilepsy.</p> <p> </p>
Researchers at the Francis Crick Institute, UCL, and MSD have identified a potential treatment target for a genetic type of epilepsy. Developmental and epileptic encephalopathies are rare types of epilepsy that start in early childhood. One of the most common types of genetic epilepsy, CDKL5 defi